Anktiva (nogapendekin alfa inbakicept-pmln) injection

ANKTIVA is a prescription medicine used to treat bladder cancer. FDA approved nogapendekin alfa inbakicept-pmln (brand name ANKTIVA) is not (yet) registered or available in India but on request Indian patient can buy ANKTIVA at the lowest price.

Anktiva-nogapendekin-inbakicept-Price-Delhi-India
Anktiva (nogapendekin alfa inbakicept-pmln)

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Anktiva (nogapendekin alfa inbakicept-pmln)

Nogapendekin alfa inbakicept is indicated with Bacillus Calmette-Guérin for adults with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

ANKTIVA is a drug to activate the immune system (the body system that helps fight disease) used together with another drug called Bacillus Calmette-Guerin (BCG) to treat a subtype of non-muscle invasive bladder cancer (NMIBC), called carcinoma in situ (CIS). It is used in patients for whom BCG treatment was not effective in treating their bladder cancer. This means that the disease either did not improve on treatment or recurred following treatment with BCG.

Nogapendekin alfa inbakicept is indicated with Bacillus Calmette-Guérin for adults with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Nogapendekin alfa inbakicept was approved for medical use in the United States in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

BLA 761336
Drug Name: Anktiva
Active Ingredient: nogapendekin alfa inbakicept-pmln
Approval Date: 4/22/2024
FDA-approved use on approval date: To treat bladder cancer
Company: Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.

Dosage Forms And Strengths: 400 mcg/0.4 mL, clear to slightly opalescent and colorless to slightly yellow solution in single-dose vials for intravesical instillation after dilution.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.